Correction: van de Velde et al. Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). Cancers 2020, 12, 3745

Error in Table

In the original publication, there was a mistake in Table 1 as published [1]. The number of patients with death was swapped between the one-hour administration group and the push administration group. The corrected

Table 1. Demographic and clinical characteristics of the participants at baseline.

	One-Hour Administration Group (n = 45)	Push Administration Group (n = 45)
Sex
Male	26 (58)	24 (53)
Female	19 (42)	21 (47)
Age, years (mean(SD))	9.06 (5.11)	9.29 (5.25)
Age ≥ 5 years and included for ped-mTNS assessment	32 (71)	34 (76)
Disease
Acute lymphoblastic leukemia	29 (64)	29 (64)
Hodgkin lymphoma	7 (16)	11 (24)
Nephroblastoma	6 (13)	2 (4)
Medulloblastoma	1 (2)	1 (2)
Rhabdomyosarcoma	2 (4)	0 (0)
Low-grade glioma	0 (0)	2 (4)
Ancestry a
Europe	36 (80)	37 (82)
Eastern Asia	1 (2)	0 (0)
Latin-America (including Caribbean)	1 (2)	2 (4)
Middle-East (including Northern Africa)	3 (7)	3 (7)
Sub-Saharan Africa	1 (2)	0 (0)
Combination	2 (4)	3 (7)
Missing	1 (2)	0 (0)
No. (%) of patients needing VCR dose reductions or omissions	1 (3)	0 (0)
No. (%) of patients using analgesics for neuropathic pain	9 (20)	11 (24)
Relapse (No. (%))	2 (4)	1 (2)
Death (No. (%))	3 (7)	1 (2)

Values represent the number (%) of participants, unless indicated otherwise. SD: standard deviation; ped-mTNS: pediatric modified Total Neuropathy Score; VCR: vincristine, ^a: Ancestry was self- or parent-reported; participants could only be included in one category.

appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.